Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company -- Ignore unavailable to you. Want to Upgrade?

To: rareearth42 who wrote (67)	11/26/2006 1:45:03 PM
From: former_pgs	Respond to of 90

It's sure getting hit hard. My concern would be the endpoints of the nsclc trial, which I've brought up before. But my concerns (minutiae) are rarely the street concerns, so there must be something else like the impending financing. Only other thing that I can think of is if someone uncovered a bias in the way that they followed patients for progression in their phase II nsclc trial. But still, there are two complete responses and a strong 1 year survival result to overcome that concern somewhat, though not completely. PS: I did get a pm from you a while ago, but can't reply because I'm too cheap to pay for a subscription. Once a pgs, always a pgs I guess. I'm trying to use poorgradstudent73@gmail.com for correspondence.